Deep Dive: Market Access
It’s fair to say this is the most interesting time ever for market access. Not only has COVID forced companies, governments and healthcare systems to work towards approving drugs and vaccines in record times, the sector is also facing an influx of digital therapeutics and advanced drugs that don’t fit neatly into existing access frameworks. We take a look at all these intersecting topics in this issue – with experts from across the industry sharing their advice on how companies can navigate these paradigm shifts.
Boehringer Ingelheim’s Carinne Brouillon tells us how the company co-created its recent Global Patient Partnership Summit with patients.
A recent analysis delves into the challenges companies face in getting digital health technologies reimbursed and presents recommendations for how they can find a smoother path to market.
Leela Barham takes stock of the NICE Methods Review and what it could mean for the industry.
NICE has a global reputation as a pioneering HTA – but is that influence at risk now that the UK has left the EU? Experts from ICON give us their views on the past, present and future of NICE’s standing on the world stage.
Savana’s Dr Ignacio Medrano explains how natural language processing technology is opening up huge amounts of previously-inaccessible real-world evidence for pharma and regulators.
IQVIA’s Liz Murray takes us through the company’s latest research into HCPs’ attitudes to pharma engagement, and asks how pharma sales forces can adapt for future changes.
IQVIA’s John Procter explores why the industry should be paying attention to the changing customer experience in the wake of COVID-19.
Rebecca Sanders from Lipodystrophy UK tells us how the patient voice helped convince NICE to approve a much-needed drug for this rare disease, and explores how regulators and pharma companies can help make patient involvement in HTA more impactful.
Experts from Vynamic discuss their vision for a future where patients are at the heart of medicine reimbursement in Europe – and provide actionable steps for achieving this.
Market access issues don’t stop once a product has passed HTA – and this is especially true for disruptive therapies like ATMPs. Experts from Executive Insight discuss how a holistic, multi-stakeholder approach can help companies overcome access barriers at all stages.
Value can mean different things to different payers. Cecilie Alstad, senior analyst at Research Partnership, discusses how an approach established in the world of marketing and commercial strategy could be the key to significantly improving pharma’s payer engagement.
How can the industry listen to patients in a way that puts the person behind the disease first? Blogger Chris Aldred and Joe Delahunty from Ascensia discuss what the industry often gets wrong in its patient engagement.
Alberto Vicent, vice president and general manager Southern Europe of PTC Therapeutics, tells pharmaphorum why we need to view ultra-rare populations differently, so they can also access treatments.
• Read the latest issue Deep Dive: Market Access 2021 in full
pharmaphorum’s digital magazine Deep Dive provides objective, issue-driven views, analysis, high-level interviews and unique research for pharmaceutical companies, biotech firms and the wider healthcare sector.
In 2020 Deep Dive will have special focuses on disruptive technologies in pharma, R&D innovation, market access and commercialisation, oncology, sales & marketing innovation, digital health and patient engagement. Subscribe to future issues of Deep Dive.